SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joseph Ziebarth who wrote (34)3/14/1997 9:28:00 AM
From: Chris Nevil   of 670
 
On this morning's newswire -- maybe this will help our cause?

Subj: ProCyte Receives FDA Clearance for Hair Transplant Wound Dressings
Date: 97-03-14 08:33:12 EST
From: AOLNewsProfiles@aol.net

Company Continues to Expand Wound Care Product Portfolio
KIRKLAND, Wash., March 14 /PRNewswire/ -- ProCyte Corporation
(Nasdaq: PRCY) today said that it has received 510(k) device clearance from
the United States Food and Drug Administration to market a gauze wound
dressing that contains the company's patented copper peptide technology.
The new product, called GraftCyte(TM) Moist Dressings, will be promoted
for use in hair restoration procedures, and is scheduled for market release in
April 1997. According to industry sources, hair restoration is one of the
leading elective medical procedures that men and women in the United States
undergo.
The hair restoration process involves a surgical procedure in which
healthy, hair-producing follicles are transplanted from areas of dense hair
growth to other areas of the scalp where fewer follicles are growing.
One of outcomes of this procedure is that the transplanted, actively
growing -- anagen phase -- follicles enter into a dormant phase, or are shed
in a process known as telogen effluvium. Typically, within three to six
months after surgery, the successfully transplanted follicles will begin to
again produce hair.
Clinical evaluation of GraftCyte(TM) Moist Dressings showed a significant
reduction in the telogen effluvium period due to the effective promotion of
natural wound healing. The topically applied GraftCyte(TM) Moist Dressings
incorporate ProCyte's patented copper peptide technology in a gel impregnated
gauze. The copper peptide has been shown to provide an essential
micronutrient that helps to maintain the optimal environment for healing and
revascularization of the graft site.
"The FDA's clearance of this dressing allows ProCyte to offer another
unique copper-containing product for use in specific types of wounds," said
Jack Clifford, ProtCyte's president and chief executive officer. "The
clinical evaluation of this dressing shows that it contributes significantly
to treatment outcomes."
ProCyte is a development-stage healthcare company that is developing and
marketing innovative copper peptide-containing or polymer-based products for
acute and chronic wound care and dermatological and plastic surgery
applications.
SOURCE ProCyte Corp.
CO: ProCyte Corp.
ST: Washington
IN: MTC
SU: PDT
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News